Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages

Journal of Biomedical Nanotechnology

Volumn 9, Issue 6, 2013, Pages 1076-1087

  Moretton, Marcela A ^a,b   Chiappetta, Diego A ^a,b   Andrade, Fernanda ^c   Das Neves, José ^c,d   Ferreira, Domingos ^c   Sarmento, Bruno ^c,d,e   Sosnik, Alejandro ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^e INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Active drug targeting to macrophages; Chitosan nanoparticles; Flower like polymeric micelles; Hydrolyzed galactomannan; Rifampicin; Tuberculosis

Indexed keywords

ACTIVE DRUGS; CHITOSAN NANOPARTICLES; GALACTOMANNANS; POLYMERIC MICELLE; RIFAMPICIN; TUBERCULOSIS;

ANTIGEN-ANTIBODY REACTIONS; CHITOSAN; ENCAPSULATION; ETHYLENE; FLUORESCENCE MICROSCOPY; HYDROLYSIS; MACROPHAGES; MICELLES; NANOPARTICLES; TUBES (COMPONENTS); ZETA POTENTIAL;

POLYMERS;

CONCANAVALIN A; GALACTOMANNAN; GALACTOSE; MANNOSE; NANOCARRIER; NANOPARTICLE; POLY(EPSILON CAPROLACTONE) B POLY(ETHYLENE GLYCOL) B POLY(EPSILON CAPROLACTONE); POLYMER; RIFAMPICIN; UNCLASSIFIED DRUG;

AGGLUTINATION TEST; ANIMAL CELL; ARTICLE; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IN VITRO STUDY; MACROPHAGE; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; VISCOSITY; ZETA POTENTIAL;

ANIMALS; CELL LINE; HYDROLYSIS; MACROPHAGES; MANNANS; MATERIALS TESTING; MICE; MICELLES; MOLECULAR TARGETED THERAPY; NANOCAPSULES; POLYMERS; RIFAMPIN;

EID: 84877815633     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1600     Document Type: Article

References (69)

1. WHO, Global tuberculosis control: Surveillance, planning, financing. World Health Organization: Geneva, Switzerland. http://www.who.int/tb/ publications/global-report/2008/pdf/fullreport.pdf (2008), (Accessed July 2010).
2. S. H. Kaufmann and A. J. McMichael, Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis. Nat. Med. 11, S33 (2005).
3. T. R. Frieden, T. R. Sterling, S. S. Munsiff, C. J. Watt, and C. Dye, Tuberculosis. Lancet 362, 887 (2003).
4. S. Sharma, P. K. Sharma, N. Kumar, and R. Dudhe, A review on various heterocyclic moieties and their antitubercular activity. Biomed. Pharmacother. 65, 244 (2011).
5. S. Bertel Squire and S. Thomson, in Tuberculosis-A comprehensive clinical reference, Edited by H. Simon Schaaf, A. L. Zumla, J. M. Grange, M. C. Raviglione, W. W. Yew, J. R. Starke, M. Pai, and P. R. Donald, Saunders Elsevier, London (2009), pp. 908-915.
6. WHO, WHO declares tuberculosis a global emergency. Soc. Prevent. Med. 38, 251 (1993).
7. WHO, Treatment of tuberculosis: guidelines, 4th Ed. World Health Organization: Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/ 9789241547833-eng.pdf (2010), (Accessed August 2012).
8. E. C. Rivers and R. L. Mancera, New antituberculosis drugs in clinical trials with novel mechanism of action. Drug Discov. Today 13, 1090 (2008).
9. A. Matteelli, A. Carvalho, K. E. Dooley, and A. Kritski, TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 5, 849 (2010).
10. S. T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C.E. 3rd. Barry, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell, Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature 393, 537 (1998).
11. WHO, The top ten causes of death. World Health Organization: Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs310/en/index.html (2011) (Accessed August 2012).
12. P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing, and N. Ford, Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 359, 2188 (2002).
13. A. Sosnik, A. M. Carcaboso, R. J. Glisoni, M. A. Moretton, and D. A. Chiappetta, New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv. Drug Deliv. Rev. 62, 547 (2010).
14. R. Pandey and G. K. Khuller, Antitubercular inhaled therapy: Opportunities, progress and challenges. J. Antimicrob. Chemother. 55, 430 (2005).
15. F. Andrade, D. Ferreira, A. Sosnik, and B. Sarmento, in Emerging Topics in Nanotechnology, Edited by A. Eftekhari, John Wiley & Sons, New York (2012), in press.
16. Y. Han, L. Zhao, Z. Yu, J. Feng, and Q. Yu, Role of mannose receptor in oligochitosan-mediates stimulation of macrophage function. Int. Immunopharmacol. 5, 1533 (2005).
17. H-L. Jiang, M-L. Kang, J-S. Quan, S-G. Kang, T. Akaike, and H. S. Yoo, The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 29, 1931 (2008).
18. J. M. Irache, H. H. Salman, C. Gamazo, and S. Espuelas, Mannosetargeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5, 703 (2008).
19. E. H. Song, M. J. Manganiello, Y. H. Chow, B. Ghosn, A. J. Convertine, P. S. Stayton, L. M. Schnapp, and D. M. Ratner. In vivo targeting of alveolar macrophages via RAFT-based glycopolymers. Biomaterials 33, 6889 (2012).
20. R. Duncan, Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688 (2006).
21. M. Alonso-Sande, D. Teijeiro-Osorio, C. Remuñán- López, and M. J. Alonso, Glucomannan, a promising polysaccharide for biopharmaceutical purposes. Eur. J. Pharm. Biopharm. 72, 453 (2009).
22. V. K. Mourya and N. N. Inamdar, Chitosan-modifications and applications opportunities galore. React. Funct. Polym. 68, 1013 (2008).
23. K. Nagpal, S. K. Singh, and D. N. Mishra, Chitosan nanoparticles: A promising system in novel drug delivery. Chem. Pharm. Bull. 58, 1423 (2010).
24. F. Andrade, F. Goycoolea, D. A. Chiappetta, J. das Neves, A. Sosnik, and B. Sarmento, Chitosan-grafted copolymers and chitosan-ligand conjugates as matrices for pulmonary drug delivery. Int. J. Carbohydr. Chem. Art. 865704 (2011).
25. A. Nasti, N. M. Zaki, P. de Leonardis, S. Ungphaiboon, P. Sansongsak, M. G. Rimoli, and N. Tirelli, Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: Systematic optimisation of the preparative process and preliminary biological evaluation. Pharm. Res. 26, 1918 (2009).
26. S. Rodrigues, A. M. R. da Costa, and A. Grenha, Chitosan/carrageenan nanoparticles: Effect of cross-linking with tripolyphosphate and charge ratios. Carbohydr. Polym. 89, 282 (2012).
27. M. L. Manca, M. Manconi, D. Valenti, F. Lai, G. Loy, P. Matricardi, and A. M. Fadda, Liposomes coated with chitosan-xanthan gum (chitosomes) as potential carriers for pulmonary delivery of rifampicin. J. Pharm. Sci. 101, 566 (2012).
28. A. Jayasree, S. Sasidharan, M. Koyakutty, S. Nair, and D. Menon, Mannosylated chitosan-zinc sulphide nanocrystals as fluorescent bioprobes for targeted cancer imaging. Carbohydr. Polym. 85, 37 (2011).
29. S. S. Chakravarthi and D. H. Robinson, Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int. J. Pharm. 409, 111 (2011).
30. P. Fonte, T. Nogueira, C. Gehm, D. Ferreira, and B. Sarmento, Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. DrugDeliv. Transl. Res. 1, 299 (2011).
31. L. C. du Toit, V. Pillay, and M. P. Danckwerts, Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res. 7, 118 (2006).
32. C. J. Shishoo, S. A. Shah, I. S. Rathod, S. S. Savale, J. S. Kotecha, and P. B. Shah, Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm. 190, 109 (1999).
33. S. Singh, T. T. Mariappan, N. Sharda, S. Kumar, and A. K. Chvakrabarti, The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Comm. 6, 405 (2000).
34. M. A. Moretton, R. J. Glisoni, D. A. Chiappetta, and A. Sosnik, Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf. B Biointerfaces 79, 467 (2010).
35. J. B. Pristov, A. Mitrovic, and I. Spasojevic, A comparative study of antioxidative activities of cell-wall polysaccharides. Carbohydr. Res. 346, 2255 (2011).
36. B. Sarmento, D. Mazzaglia, M. C. Bonferoni, A. P. Neto, M. Monteiro, and V. Seabra, Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr. Polym. 84, 919 (2011).
37. D. R. Picout and S. B. Ross-Murphy, On the Mark-Houwink parameters for galactomannans. Carbohydr. Polym. 70, 145 (2007).
38. R. J. Young and P. A. Lovell, Editors, Introduction to polymers, Vol. 2, Chapman & Hall. New York (1991).
39. R. Sankar, N. Sharda, and S. Singh, Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev. Ind. Pharm. 29, 733-738 (2003).
40. C. J. Shishoo, S. A. Shah, I. S. Rathod, and S. S. Savale, Impared bioavailability of rifampicin from fixed dose combinations (FDC) formulations with isoniazid. Indian J. Pharm. Sci. 63, 443 (2001).
41. L. Chen, Z. Xie, J. Hu, X. Chen, and X. Jing, Enantiomeric PLA-PEG block copolymers and their stereocomplex micelles used as rifampin delivery. J. Nanopart. Res. 9, 777 (2007).
42. S. K. Mehta, N. Jindal, and G. Kaur, Quantitative investigation, stability and In vitro release studies of anti-TB drugs in triton niosomes. Colloids Surf. B Biointerfaces 87, 173 (2011).
43. S. K. Mehta and N. Jindal, Formulation of tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs. Colloids Surf. B Biointerfaces 101, 434 (2013).
44. H. Morawetz and W. L. Hughes, The interaction of proteins with synthetic polyelectrolytes I. Complexing of bovine serum albumin. J. Phys. Chem. 56, 64 (1952).
45. J. das Neves, J. Michiels, K. K. Ariën, G. Vanham, M. Amiji, M. F. Bahia, and B. Sarmento, Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine. Pharm. Res. 29, 1468 (2012).
46. I. Calleja, M. J. Blanco-Prieto, N. Ruz, M. J. Renedo, and M. C. Dios-Viéitez, High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. J. Chromatogr. A 130, 289 (2004).
47. W. Lin, Q. Li, and T. Zhu, New chitosan/Konjac glucomannan blending membrane for application in pervaporation dehydration of caprolactam solution. J. Ind. Chem. Eng. 18, 934 (2012).
48. M. Samil Kök, Rheological study of galactomannan depolymerization at elevated temperatures: Effect of varying pH and addition of antioxidants. Carbohydr. Polym. 81, 567 (2010).
49. M. A. Moretton, D. A. Chiappetta, and A. Sosnik, Cryoprotection- lyophilization and physical stabilization of rifampicin loaded flowerlike polymeric micelles. J. Royal Soc. Interface 9, 487 (2012).
50. L. Mazzarino, C. Travelet, S. Ortega-Murillo, I. Otsuka, I. Pignot-Paintrand, E. Lemos-Senna, and R. Borsali, Elaboration of chitosancoated nanoparticles loaded with curcumin for mucoadhesive applications. J. Colloid. Interface Sci. 370, 58 (2012).
51. X. Wang, O. Ramström, and M. Yan, Dynamic light scattering as an efficient tool to study glyconanoparticle-lectin interactions. Analyst 136, 4174 (2011).
52. J. Bouckaert, R. Loris, and L. Wyns, Zinc/calcium- and cadmium/cadmium-substituted concanavalin A: interplay of metal binding, pH and molecular packing. Acta Crystallogr. D Biol. Crystallogr. 56, 1569 (2000).
53. A. Štimac, S. Šegota, M. Dutour Sikirić, R. Ribić, L. Frkanec, V. Svetličić, S. Tomić, B. Vranešić, and R. Frkanec, Surface modified liposomes by mannosylated conjugates anchored via the adamantly moiety in the lipid bilayer. Biochim. Biophys. Acta 1818, 2252 (2012).
54. G. Sánchez-Pomales, T. A. Morris, J. B. Falabella, M. J. Tarlov, and R. A. Zangmeister, A lectin-based gold nanoparticle assay for probing glycosylation of glycoproteins. Biotechnol. Bioeng. 109, 2240 (2012).
55. Y. Anraku, Y. Takahashi, H. Kitano, and M. Hakari, Recognition of sugars on surface-bound cap-shaped gold particles modified with a polymer brush. Colloids Surf. B Biointer. 57, 61 (2007).
56. R. Yin, Z. Tong, D. Yang, and J. Nie, Glucose-responsive insulin delivery microhydrogels from methacrylated dextran/concanavalin A: Preparation and In vitro release study. Carbohydr. Polym. 89, 117 (2010).
57. M-X. Hu and Z-K. Xu, Carbohydrate decoration of microporous polypropylene membranes for lectin affinity adsorption: Comparison of mono- and disaccharides. Colloids Surf. B Biointerfaces 85, 19 (2011).
58. X. Wang, L. H. Liu, O. Ramström, and M. Yan, Engineering nano-material surfaces for biomedical applications. Exp. Biol. Med. 234, 1128 (2009).
59. Y. H. Choi, F. Liu, J. S. Park, and S. W. Kim, Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-targeted gene carrier. Bioconjug. Chem. 9, 708 (1998).
60. D. A. Chiappetta, C. Hocht, J. A. W. Opezzo, and A. Sosnik, Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Land.) 8, 223 (2003).
61. T. Onoshita, Y. Shimizu, N. Yamaya, M. Miyazaki, M. Yokoyama, N. Fujiwara, T. Nakajima, K. Makino, H. Terada, and M. Haga, The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf. B. Biointerfaces 76, 151 (2010).
62. K. Hirota, T. Hasegawa, H. Hinata, F. Ito, H. Inagawa, C. Kochi, G. I. Soma, K. Makino, and H. Terada, Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release 119, 69 (2007).
63. K. Hirota, T. Hasegawa, T. Nakajima, K. Makino, and H. Terada, Phagostimulatory effect of uptake of PLGA microspheres loaded with rifampicin on alveolar macrophages. Colloids Surf. B Biointerfaces 87, 293 (2011).
64. M. Dutt and G. K. Khuller, Liposomes and PLG microparticles as sustained release antitubercular drug carriers - an In vitro-in vivo study. Int. J. Antimicrob. Agents. 18, 245 (2001).
65. K. Makino, N. Yamamoto, K. Higuchi, N. Harada, H. Ohshima, and H. Terada, Phagocytic uptake of polystyrene microspheres by alveolar macrophages: Effects of the size and surface properties of the microspheres. Colloids Surf. B Biointerfaces 27, 33 (2003).
66. E. Almouazen, S. Bourgeois, A. Boussaïd, P. Valot, C. Malleval, H. Fessi, S. Nataf, and S. Briançon, Development of a nanoparticle-based system for the delivery of retinoic acid into macrophages. Int. J. Pharm. 430, 207 (2012).
67. A. V. Chavez-Santoscoy, R. Roychoudhury, N. L. B. Pohl, M. J. Wannemuehler, B. Narasimhan, and A. E. Ramer-Tait, Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using "pathogen-like" amphiphilic polyanhydride nanoparticles. Biomaterials 33, 4762 (2012).
68. M. K. Yoo, I. Y. Park, I. Y. Kim, I. K. Park, J. S. Kwon, H. J. Jeong, Y. Y. Jeong, and C. S. Cho, Superparamagnetic iron oxide nanoparticles coated with mannan for macrophage targeting. J. Nanosci. Nanotechnol. 8, 5196 (2008).
69. T. Hasegawa, K. Iijima, K. Hirota, T. Nakajima, K. Makino, and H. Torada, Exact determination of phagocytic activity of alveolar macrophages toward polymer microspheres by elimination of those Scieantttaicfhiced Ptoubthlieshmeacrrsophage membrane. Colloids Surf. B Biointerfaces 63, 209 (2008).